Response to avapritinib by AdvSM subtype (prior systemic therapy pooled efficacy population)
| Best response . | Prior systemic therapy pooled efficacy population (n = 31) . | |||
|---|---|---|---|---|
| All AdvSM (n = 31) . | ASM (n = 1) . | SM-AHN (n = 22) . | MCL (n = 8) . | |
| ORR, % (95% CI) (CR+CRh+PR+CI) | 71 (52-86) 22/31 | 100 (3-100) 1/1 | 77 (55-92) 17/22 | 50 (16-84) 4/8 |
| CR, n (%) | 1 (3) | 0 | 1 (5) | 0 |
| CRh, n (%) | 5 (16) | 1 (100) | 4 (18) | 0 |
| PR, n (%) | 14 (45) | 0 | 10 (46) | 4 (50) |
| CI, n (%) | 2 (6) | 0 | 2 (9) | 0 |
| SD, n (%) | 4 (13) | 0 | 1 (5) | 3 (38) |
| PD, n (%) | 1 (3) | 0 | 0 | 1 (13) |
| NE, n (%) | 4 (13) | 0 | 4 (18) | 0 |
| Best response . | Prior systemic therapy pooled efficacy population (n = 31) . | |||
|---|---|---|---|---|
| All AdvSM (n = 31) . | ASM (n = 1) . | SM-AHN (n = 22) . | MCL (n = 8) . | |
| ORR, % (95% CI) (CR+CRh+PR+CI) | 71 (52-86) 22/31 | 100 (3-100) 1/1 | 77 (55-92) 17/22 | 50 (16-84) 4/8 |
| CR, n (%) | 1 (3) | 0 | 1 (5) | 0 |
| CRh, n (%) | 5 (16) | 1 (100) | 4 (18) | 0 |
| PR, n (%) | 14 (45) | 0 | 10 (46) | 4 (50) |
| CI, n (%) | 2 (6) | 0 | 2 (9) | 0 |
| SD, n (%) | 4 (13) | 0 | 1 (5) | 3 (38) |
| PD, n (%) | 1 (3) | 0 | 0 | 1 (13) |
| NE, n (%) | 4 (13) | 0 | 4 (18) | 0 |
Percentages have been rounded to whole numbers and may not add up to 100%.
NE, not evaluable.